Pivot Park Screening Centre (PPSC) and Center for Mass Spectrometry and Optical Spectroscopy (CeMOS) form a strategic partnership for joint label-free cellular lead discovery screening services

Oss, the Netherlands and Mannheim, Germany – 21 February 2022

PPSC and CeMOS have formed a strategic partnership to provide industry-leading joint early drug discovery services, with an emphasis on label-free “cell-based” target-centric, phenotypic, and functional MALDI MS assays for ultra-High-Throughput Screening (uHTS), hit-to-lead biological profiling and in-vitro DMPK/ADME-T. The recent successful industrialization of conventional biochemical Mass Spectrometry (MS) uHTS assays for various target classes and several large-scale uHTS campaigns at PPSC, along with a decade of cellular MS assay development experience at CeMOS with broad applications for uHTS of large compound collections and medium throughput hit-to-lead & in-vitro DMPK/ADME-T biological profiling, as recently summarized in Unger M.S., et al. Nature Protocols 16, 5533–5558 (2021) supports a strategic shift towards cost-effective cell-based MS technologies in miniaturized formats to deliver de-risked chemical starting points for difficult-to-assay targets, signaling pathways and phenotypes in complex in-vitro disease models to accelerate lead discovery.

Mathias Hafner, Vice President of Research, Mannheim University of Applied Sciences – “We are very happy that our flagship research and transfer center CeMOS can contribute to the important search for so urgently needed new medical options. “

Brigitte Drees, CEO, PPSC – “With the unique partnership between PPSC – CeMOS, we are able to accelerate the early drug discovery of potential future medicines.”

Carsten Hopf, Head of CeMOS at Mannheim University of Applied Sciences   – “The strong partnership with Pivot Park Screening Centre offers a unique opportunity to take MALDI mass spectrometry cell assays pioneered at CeMOS to industrial scale.”

Saman Honarnejad, CSO, PPSC – “This partnership addresses the increasing market demand for cellular and phenotypic label-free MS-based screening method development. Our joint capabilities as we have assembled them in this strategic partnership, creates a highly differentiated and competitive label-free service portfolio for our clients across the globe to accelerate the discovery of new medicines.”

Pivot Park Screening Centre (PPSC) in Oss, the Netherlands was established in 2012 as a spin-off Contract Research Organization (CRO) from former Organon/MSD screening unit. PPSC specializes in early drug discovery services in the fields of assay development, lab automation, ultra-High-Throughput Screening (uHTS) and hit-to-lead biological profiling to find novel leads for drug development. PPSC continuously expands its early drug discovery know-how, compound library and services to add value to our vibrant client network and the pharmaceutical R&D community.

The Center Mass Spectrometry and Optical Spectroscopy (CeMOS) in Mannheim, Germany is engaged in the development and automation of prototype cellular MALDI mass spectrometry (MS) test systems with applications across various stages of drug discovery. Over the last decade, CeMOS has pioneered a series of MALDI-TOF MS mechanistic and phenotypic cellular assays amenable to biomarker discovery, HTS, H2L and DMPK. The technological leadership of CeMOS in the fields of mass spectrometry, Raman, mid-infrared, UV, VIS, and fluorescence measurement techniques, as well as the possibilities of AI-supported image-based presentation and calculation of the results, creates a unique synergy with PPSC for joint drug discovery services.

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?


The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.